ORKA
The table below shows Oruka Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.58M | -$20.87M | -$1.53M | -$1.59M | -$4.30M | -$5.22M |
| Capital expenditure | $73.00K | $13.00K | - | - | $2.00K | $6.00K |
| Investing cash flow | -$14.44M | $42.87M | $0.00 | $0.00 | -$2.00K | -$6.00K |
| Dividends paid | - | - | - | - |
Oruka Therapeutics, Inc. reported operating cash flow of -$88.21M for fiscal year 2025. That is down 52.5% from -$57.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.29M (FY 2013) to -$88.21M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $40.60M | - | $0.00 | $0.00 | - | $23.09M |